HUNTINGTON BEACH, California and AMSTERDAM, December 12 (HSMN NewsFeed) — Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint®’s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura v…
Diagnostics, Oncology
Agendia, MammaPrint, breast cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Agendia’s MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer”
Leave a Comment